Crown Bioscience extends portfolio of humanised drug target models to San Diego facility

Global drug discovery and development services company, Crown Bioscience, has extended its existing portfolio of humanised drug target models (HuGEMM) to its San Diego facility.

Beginning with humanised PD-1, PD-L1, CTLA-4, OX40, CD137, PD-1/PD-L1, and PD-1/CTLA-4 targets, the extension to the San Diego site is expected to increase through the addition of other HuGEMM models later on in the year that will help advanced development of immune-oncology (I/O) drugs.

“Our HuGEMM portfolio is uniquely positioned to expedite study timelines, save researcher's money and deliver valuable insights about targeted immunotherapies,” said Henry Li, PhD, senior vice president of Global Scientific Research and Innovation. “We are very excited about continuing to grow this platform and to make it more available to scientists globally via the expansion of our San Diego laboratory.”

The expansion of this novel translational platform to CrownBio’s San Diego laboratory makes it more accessible to both the North American and worldwide research community.